...
首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
【24h】

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management

机译:逐步降低或治疗性组织重组以戒断某些COPD患者吸入性糖皮质激素的框架:COPD管理的建议

获取原文
           

摘要

While chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well as the frequency and severity of exacerbations, and general health. The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] + inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and without control using a LABA/LAMA or ICS/LABA combination. Long-term monotherapy with ICS is not currently recommended, but may be considered in association with LABAs in patients with a history of exacerbations and elevated eosinophils in spite of appropriate treatment with long-acting bronchodilators. However, long-term use of ICS in combination therapy has been associated with adverse effects, even if widely used in routine management for decades. The available evidence suggests that ICS can be rationally discontinued in patients with stable disease and is not likely to have unfavorable effects on lung function, overall health, or be associated with a greater risk of exacerbations. Indeed, it is widely accepted that ICS therapy should be limited to a small proportion of patients after careful assessment of the individual risk-benefit profile. Unfortunately, however, there are no international recommendations that provide specific guidance or a protocol for withdrawal of ICS. Herein, the available evidence on the use of ICS is reviewed and an easy to use tool is proposed that can provide clinicians with a simple management scheme to guide the most appropriate therapy for management of COPD and use of ICS. In management of COPD, a highly personalized approach is advocated so that the most appropriate therapy for each individual patient can be selected.
机译:尽管慢性阻塞性肺疾病(COPD)仍然是发病率和死亡率的主要原因,但药物治疗对症状,加重的频率和严重程度以及总体健康具有明显的益处。最新的《全球阻塞性肺疾病倡议》(GOLD)指南建议仅针对加重,嗜酸性粒细胞增高,而无需使用LABA / LAMA或ICS / LABA组合进行控制。目前不建议使用ICS进行长期单药治疗,但即使长期使用支气管扩张剂适当治疗,也可考虑与LABA联合用于有恶化史和嗜酸性粒细胞升高的患者。但是,即使数十年来在常规治疗中广泛使用ICS,长期将其用于联合治疗也已产生不良反应。现有证据表明,在疾病稳定的患者中,可以合理地停用ICS,并且不太可能对肺功能,整体健康产生不利影响,也不会导致病情加重。的确,在认真评估个人风险收益特征后,ICS治疗应限于一小部分患者,这一点已被广泛接受。但是,不幸的是,没有国际建议为撤回ICS提供具体指导或协议。在此,对有关使用ICS的现有证据进行了综述,并提出了一种易于使用的工具,该工具可为临床医生提供简单的管理方案,以指导最适合治疗COPD和使用ICS的疗法。在COPD的管理中,提倡高度个性化的方法,以便为每个患者选择最合适的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号